Aegis Therapeutics has received US patent covering pharmaceutical composition of octreotide.
The octreotide formulations incorporate Aegis’ Intravail/ProTek excipients suitable for all routes of administration including oral, buccal, metered nasal spray, or injection.
The Intravail/ProTek excipients allow for non-invasive delivery with high efficiency, which stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics.
The excipients even avoid the oxidative damage caused by polysorbate surfactants, the company said.
Octreotide is a peptide hormone and is used to treat acromegaly, severe diarrhea and flushing episodes associated with metastatic carcinoid tumors, and profuse watery diarrhea associated with Vasoactive Intestinal Peptide Tumors. A preclinical study demonstrated that formulations of octreotide incorporating Intravail/ProTek excipients show oral bioavailability that equals or exceeds that achieved by injection, offering the prospect of a non-injectable octreotide.